2025-04-16 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis

**0. Executive Summary:**

Johnson & Johnson (JNJ), a multinational healthcare corporation, shows a cumulative return significantly lagging behind the S&P 500 (VOO) over the observed period. While exhibiting relatively stable profitability and revenue, recent performance indicates underperformance against the market benchmark, with concerning negative trends in key indicators. Further investigation is needed to determine the long-term investment viability.


**1. Performance Comparison with S&P 500 (VOO):**

Johnson & Johnson (JNJ) is a diversified healthcare company producing medical devices, pharmaceuticals, and consumer goods.

* **JNJ Cumulative Return:** 24.71%
* **VOO (S&P 500) Cumulative Return:** 66.27%
* **Return Difference:** -41.6%  This indicates JNJ significantly underperformed the S&P 500.  The relative divergence of -37.1% places it at the lower end of its historical range compared to VOO, highlighting this underperformance.

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 28.0% | 56.0% | -1.0% | 0.0 | 275.3 |
| 2016-2018  | 10.0% | 10.8% | -7.0% | 0.0 | 261.2 |
| 2017-2019  | 20.0% | 10.8% | -9.0% | 0.7 | 303.6 |
| 2018-2020  | 14.0% | 59.8% | -12.0% | 0.5 | 336.4 |
| 2019-2021  | 28.0% | 59.9% | -26.0% | 0.3 | 374.9 |
| 2020-2022  | 4.0% | 61.2% | -2.0% | 0.3 | 397.3 |
| 2021-2023  | -19.0% | 61.2% | -35.0% | 0.4 | 363.2 |
| 2022-2024  | -31.0% | 61.2% | -47.0% | 0.3 | 345.7 |
| 2023-2025  | -2.0% | 69.6% | -0.2 | 0.2 | 370.2 |

The Alpha values are consistently negative, suggesting underperformance against the market benchmark.  Beta values are generally low, indicating lower volatility than the market, though this is less relevant given the significantly lower return.


**2. Recent Price Movements:**

* **Closing Price:** $153.62
* **Previous Close:** $154.36
* **Change:** -$0.48 (a small decrease)
* **5-Day Moving Average:** $151.87
* **20-Day Moving Average:** $157.50
* **60-Day Moving Average:** $157.59

The price is below all three moving averages, suggesting a downward trend.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4175 (Medium Risk)
* **RSI:** 40.53 (Approaching oversold territory, but not definitively so.)
* **PPO:** -0.39 (Negative, indicating bearish momentum.)
* **20-Day Relative Divergence Change:** -12.8% (Short-term downward trend)
* **Expected Return (vs. S&P 500):** -47.4% (Significant underperformance projected over the long term)

The combination of a negative PPO, low RSI, and negative relative divergence suggests bearish momentum. The significantly negative expected return highlights the substantial underperformance relative to the S&P 500.  The small price drop of -$0.48 doesn't represent a significant event.


**4. Recent Earnings Analysis:**

| 날짜       | EPS     | 매출           |
|------------|---------|-----------------|
| 2024-10-23 | $1.12   | $22.47 Billion  |
| 2024-07-25 | $1.95   | $22.45 Billion  |
| 2024-05-01 | $1.35   | $21.38 Billion  |
| 2024-02-16 | $1.68   | $21.39 Billion  |
| 2023-10-27 | $10.32  | $21.35 Billion  |

EPS shows significant volatility, with a large spike in October 2023. Revenue remains relatively stable.  Further investigation is needed to understand the reasons behind the EPS fluctuation.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue      | Profit Margin |
|-------------|---------------|---------------|
| 2024-12-31  | $22.52 Billion | 68.35%        |
| 2024-09-30  | $22.47 Billion | 69.01%        |
| 2024-06-30  | $22.45 Billion | 69.40%        |
| 2024-03-31  | $21.38 Billion | 69.55%        |
| 2023-12-31  | $21.39 Billion | 68.23%        |

Revenue is relatively stable. Profit margins are high and consistent, showing strong profitability.


**Capital and Profitability:**

| Quarter     | Equity        | ROE           |
|-------------|---------------|---------------|
| 2024-12-31  | $71.49 Billion | 4.80%         |
| 2024-09-30  | $70.16 Billion | 3.84%         |
| 2024-06-30  | $71.54 Billion | 6.55%         |
| 2024-03-31  | $70.02 Billion | 4.65%         |
| 2023-12-31  | $68.77 Billion | 5.89%         |

Equity shows some fluctuation, while ROE also varies.  Further analysis is needed to understand the drivers of these changes.


**6. Overall Analysis:**

JNJ exhibits strong financial fundamentals with consistent revenue and high profit margins. However, its stock performance significantly underperforms the S&P 500, with negative alpha consistently indicating underperformance against the market benchmark.  Technical indicators point to a bearish short-term trend, and the projected long-term underperformance relative to the S&P 500 is concerning.  The volatile EPS figures require further investigation.  Before making any investment decision, a thorough examination of the reasons behind the stock's underperformance and the unusual EPS spike in Q4 2023 is crucial.  Considering the current data, a long-term investment requires careful consideration of the risks associated with this significant underperformance.
